Wegovy: Promising Weight Loss Drug Comes with Important Caveats

The weight loss drug Wegovy has garnered significant attention in New Zealand, with over 18,000 prescriptions issued since its launch in July 2023. While the drug has been described as a breakthrough in weight management, health professionals caution that it is not a simple solution for weight loss as suggested by social media influencers.

Wegovy, manufactured by the same company behind the diabetes medication Ozempic, contains the active ingredient semaglutide, which helps control appetite by slowing gut motility and gastric emptying. This mechanism allows users to feel full longer, potentially leading to substantial weight loss.

Significant Benefits and Limitations

Dr. Rinki Murphy, an endocrinologist at the University of Auckland, has observed that Wegovy can be particularly beneficial for individuals suffering from severe obesity-related complications, such as type 2 diabetes and cardiovascular issues. Murphy noted, “For those patients, drugs like Wegovy made a huge difference.” Alongside weight reduction, the medication can lower the risk of developing type 2 diabetes and improve overall health outcomes.

In clinical trials, participants using Wegovy lost between 15% to 20% of their body weight, outperforming many previous weight loss drugs. Despite these promising results, Murphy emphasizes the necessity of lifestyle changes. “Weight loss is not possible without drastic lifestyle changes in conjunction with the drug,” she advised.

Dr. Jennifer Macdiarmid, a clinical adviser at WellSouth, echoes this sentiment. She highlights the importance of patient education when prescribing Wegovy. Macdiarmid explains that studies indicate weight gain often resumes after discontinuation of the drug. “It costs about $500 a month, and I wouldn’t want patients going on it thinking it was going to sort them out,” she added.

The Broader Context of Obesity

Many patients seeking Wegovy are middle-aged women, often facing hormonal changes due to perimenopause or postmenopause. Macdiarmid has observed that some believe Wegovy will resolve all their health challenges, a misconception she attributes to extensive advertising. “Before prescribing Wegovy, I discuss their eating and physical activity habits and barriers to making changes,” she noted.

Registered nutritionist Claire Turnbull, who operates Mission Nutrition in Queenstown, cautions against viewing Wegovy as a panacea for obesity. She stresses the need for a comprehensive approach to health. “It’s not just one gym workout a day; incidental movement during your day adds up,” she explained.

Turnbull also raises concerns about potential long-term impacts of Wegovy, particularly regarding muscle loss and mental health. For her clients, who are often stressed and overworked, the medication may not address underlying issues. “What is the risk-benefit in your personal situation?” she asks, urging individuals to consult healthcare professionals before considering the drug.

Sleep, according to Turnbull, is another crucial factor that people often overlook when managing weight. It significantly influences appetite hormones, and she believes a lack of sleep can exacerbate weight issues.

Both Macdiarmid and Turnbull highlight the importance of tackling the root causes of obesity, which they believe stem from modern lifestyles characterized by high consumption of sugar and processed foods. Accessing affordable healthy options is becoming increasingly challenging in New Zealand, which complicates efforts to maintain a healthy lifestyle.

In conclusion, while Wegovy presents a new avenue for weight loss, experts emphasize that it should be viewed as one part of a broader strategy to combat obesity. Individuals considering this medication must weigh its potential benefits and drawbacks carefully, ensuring they remain committed to a balanced lifestyle that includes nutrition and physical activity.